Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04448184 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial)

Study acronym: PATH
StatusRecruiting
PhasePhase 3
Started2022-02-16
View on ClinicalTrials.gov ↗

Amendment history

2026-01-06
Study Status, Contacts/Locations v6
Study sites11→12
2023-09-20
Study Status, Contacts/Locations v5
Study sitesdetails revised at 2 of 11 sites
2022-12-12
Study Status, Contacts/Locations v4
Study sites10→11
2022-06-27
Study Identification, Study Status, Contacts/Locations v3
Start dateestimated 2022-02→confirmed 2022-02-16
Study sites11→10
Study title+4 characters
Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial)
2022-02-01
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2025-09-01→2027-02
Completion date2025-12-01→2027-02
Start date2021-06-01→2022-02
Study sitesdetails revised at 11 of 11 sites
2021-05-19
Study Status, Contacts/Locations v1
Start date2020-09-01→2021-06-01
2020-06-24
Original filing
It is hypothesized that a strategy using prophylactic oral and intravenous Tranexamic Acid (TXA) with therapeutic platelet transfusions (if required) is safe and more effective than prophylactic platelet transfusions in patients undergoing an autologous hematopoietic stem cell transplantation (ASCT).
Trial Details
NCT Number NCT04448184
Lead Sponsor Ottawa Hospital Research Institute
Collaborators: Alberta Cancer Foundation
Conditions Hematologic Neoplasms
Enrollment 662 participants
Start Date 2022-02-16
Primary Completion 2027-02 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-01-08